These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33724373)

  • 21. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
    Perrier M; Charpentier C; Peytavin G; Lê M; Blondel L; Visseaux B; Joly V; Pinto A; Matheron S; Yazdanpanah Y; Descamps D; Landman R
    J Antimicrob Chemother; 2017 Jun; 72(6):1745-1751. PubMed ID: 28186251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Chinula L; Ziemba L; Brummel S; McCarthy K; Coletti A; Krotje C; Johnston B; Knowles K; Moyo S; Stranix-Chibanda L; Hoffman R; Sax PE; Stringer J; Chakhtoura N; Jean-Philippe P; Korutaro V; Cassim H; Fairlie L; Masheto G; Boyce C; Frenkel LM; Amico KR; Purdue L; Shapiro R; Mmbaga BT; Patel F; van Wyk J; Rooney JF; Currier JS; Lockman S;
    Lancet HIV; 2023 Jun; 10(6):e363-e374. PubMed ID: 37167996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
    Huhn GD; Eron JJ; Girard PM; Orkin C; Molina JM; DeJesus E; Petrovic R; Luo D; Van Landuyt E; Lathouwers E; Nettles RE; Brown K; Wong EY
    AIDS Res Ther; 2019 Aug; 16(1):23. PubMed ID: 31464642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
    Valantin MA; Bittar R; de Truchis P; Bollens D; Slama L; Giral P; Bonnefont-Rousselot D; Pétour P; Aubron-Olivier C; Costagliola D; Katlama C;
    J Antimicrob Chemother; 2010 Mar; 65(3):556-61. PubMed ID: 20053692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
    Blanco JL; Rojas J; de Lazzari E; Inciarte A; Subirana M; Callau P; Martinez-Rebollar M; Laguno M; Mallolas J; de la Mora L; Torres B; Gonzalez-Cordón A; Martinez E
    J Antimicrob Chemother; 2022 Jun; 77(7):1974-1979. PubMed ID: 35512339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
    Perez-Valero I; Llibre JM; Castagna A; Pulido F; Molina JM; Esser S; Margot N; Shao Y; Temme L; Piontkowsky D; McNicholl IR; Haubrich R
    J Acquir Immune Defic Syndr; 2021 Apr; 86(4):490-495. PubMed ID: 33315694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
    Kityo C; Hagins D; Koenig E; Avihingsanon A; Chetchotisakd P; Supparatpinyo K; Gankina N; Pokrovsky V; Voronin E; Stephens JL; DeJesus E; Wang H; Acosta RK; Cao H; Quirk E; Martin H; Makadzange T
    J Acquir Immune Defic Syndr; 2019 Nov; 82(3):321-328. PubMed ID: 31609930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
    Kabbara WK; Ramadan WH
    J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
    Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
    Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
    Maggiolo F; Gianotti N; Comi L; Di Filippo E; Fumagalli L; Nozza S; Galli L; Valenti D; Rizzi M; Castagna A
    J Antimicrob Chemother; 2020 May; 75(5):1332-1337. PubMed ID: 32129855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
    Girard PM; Cabié A; Michelet C; Verdon R; Katlama C; Mercié P; Morand-Joubert L; Pétour P; Monchecourt F; Chêne G; Trylesinski A;
    J Antimicrob Chemother; 2009 Jul; 64(1):126-34. PubMed ID: 19403652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
    Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
    J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.